STOK Aug 2024 15.000 call
| Previous close | 3.5000 |
| Open | 2.7800 |
| Bid | 2.2500 |
| Ask | 4.0000 |
| Strike | 15.00 |
| Expiry date | 2024-08-16 |
| Day's range | 2.7800 - 3.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 47 |
Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in June
BEDFORD, Mass., June 03, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:
GuruFocus.comInsider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:STOK), executed a significant stock transaction, selling 42,350 shares of the company.
Business WireStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass., May 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing
